Home   HELP  /   AYUDA  /   求助 : bctrials@quantumleaphealth.org  /   (888) 282-7099 Click to print page  Print

Browse Trials


Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.


Currently viewing trials
(Last updated: June 10, 2026)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

Brain Mets

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Leptomeningeal Disease

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: ADC

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Integrative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Healthy/High Risk

Imaging

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 353 miles
City of Hope Comprehensive Cancer Center
Duarte,CA

VISITS: 2-3 visits within 6 months

PHASE: II

NCT ID: NCT05941520

Acolbifene or Low Dose Tamoxifen to Prevent Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer Scientific Title

Purpose
To compare acolbifene and low dose tamoxifen (Nolvadex®) hormone therapies to prevent breast cancer for postmenopausal women at high risk for breast cancer.
Who is this for?
Premenopausal women at least 35 years old who have a high risk for developing breast cancer. High risk is defined below.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acolbifene, by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Breast biopsy, 2 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Breast biopsy, 2 times</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High risk is defined as at least 1 of the following: abnormal biopsy; history of DCIS or LCIS (stage 0 breast cancer); high breast density; family history; and/or an ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, or TP53 gene mutation. You must not have a BRCA1/2 or PALB2 gene mutation.</li> <li class="seamTextUnorderedListItem">People at high risk for breast cancer may receive breast MRI, ultrasound, mammograms, mastectomy, and/or tamoxifen (Nolvadex®).</li> <li class="seamTextUnorderedListItem">Estrogen can cause the development and growth of breast cancer cells. Acolbifene and tamoxifen (Nolvadex®) hormone therapies block the use of estrogen by breast cells.</li> <li class="seamTextUnorderedListItem">The dose of tamoxifen (Nolvadex®) used in this study is four times lower than the standard dose.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05941520' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/tamoxifen-and-raloxifene-for-breast-cancer-prevention.html' target='_blank'>American Cancer Society: Tamoxifen and Raloxifene for Lowering Breast Cancer Risk</a> </li></ul>
See more
2

NEAREST SITE: 752 miles
University of Arizona Cancer Center - Prevention Research Clinic
Tucson,AZ

VISITS: 4 visits within 1.5 years

PHASE: II

NCT ID: NCT06184750

Tamoxifen Hormone Therapy to Reduce Breast Density and Breast Cancer Risk for Premenopausal Women

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial Scientific Title

Purpose
To study the ability of low dose tamoxifen (Nolvadex®) to decrease breast density and breast cancer risk.
Who is this for?
Premenopausal women 18-55 years old who have a history of estrogen receptor positive (ER+) DCIS and have completed treatment at least 3 months ago, who have a history of LCIS, who have received abnormal biopsy results, or who have a high risk for breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months to 2 years</li> <li class="seamTextUnorderedListItem">Mammograms, 4 times within 1.5 years</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 1.5 years</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times (optional)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dense breasts are a risk factor for breast cancer.</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). It works by blocking the effects of the hormone estrogen in the breast.</li> <li class="seamTextUnorderedListItem">Tamoxifen reduces breast density, even at low doses, and is approved for the prevention of breast cancer.</li> <li class="seamTextUnorderedListItem">The researchers may change your tamoxifen dose according to changes in your breast density as seen on a mammogram.</li> <li class="seamTextUnorderedListItem">DCIS or LCIS are also known as stage 0 breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06184750' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
3

NEAREST SITE: 1500 miles
University of Kansas Cancer Center
Kansas City,KS

VISITS: At least 2 visits in 6 months

PHASE: II

NCT ID: NCT06195306

Tamoxifen With or Without Omega-3 Fatty Acids to Reduce the Risk of Breast Cancer for Overweight Postmenopausal Women

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer Scientific Title

Purpose
To study if tamoxifen (Nolvadex®) hormone therapy with or without omega-3 fatty acids decreases breast cancer risk in postmenopausal women who are overweight or obese.
Who is this for?
Postmenopausal women 45-65 years old who are overweight or obese and have at least 1 of the following breast cancer risk factors: abnormal biopsy results; history of DCIS (stage 0) or LCIS (stage 0); dense breasts; family history of breast cancer; or a mutation in ATM, BARD1, CDH1, CHEK2, NF1, PTEN, RAD51C, RAD51D, or STK11.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Tamoxifen Alone</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 1 time</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Tamoxifen with Omega-3 Fatty Acids</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Omega-3 fatty acids (Lovaza®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 1 time</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">Tamoxifen is approved by the FDA for preventing breast cancer in women at increased risk. </li> <li class="seamTextUnorderedListItem">Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver and may help prevent cancer in overweight or obese individuals.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06195306' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/treatments/9785-tamoxifen' target='_blank'>Cleveland Clinic: Tamoxifen (Nolvadex®)</a> </li></ul>
See more
4

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05557877

Low-Dose Aspirin to Prevent Breast Cancer After Having a Baby

Targeted Prevention of Postpartum-Related Breast Cancer Scientific Title

Purpose
To study whether low-dose aspirin prevents breast cancer in women who have recently had a baby and who have benign (non-cancerous) breast disease.
Who is this for?
Pre-menopausal women, ages 18 to 45, who have had a baby in the last 5 years, have received a mammogram that suggested benign (non-cancerous) breast disease, and are planning to receive a biopsy. You must not be taking any medication to prevent breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose aspirin, by mouth, daily</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose aspirin, a non-steroidal anti-inflammatory drug, may reduce inflammation in blood and tissue which may prevent breast cancer after having a baby.</li> <li class="seamTextUnorderedListItem">Benign breast disease is non-cancerous breast disease.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05557877' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-minute-aspirins-role-in-preventing-and-stopping-the-spread-of-cancer/' target='_blank'>Mayo Clinic: Aspirin and Cancer Prevention</a> </li></ul>
See more
5

NEAREST SITE: 1814 miles
Rush University College of Nursing
Sugar Grove,IL

VISITS: 2 visits within 6 months

PHASE: NA

NCT ID: NCT06827704

Dance Program to Improve Physical Health and Reduce the Risk of Breast Cancer for South Asian Indian Immigrant Women

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in South Asian Indian Immigrant Women (MetS-BC) Scientific Title

Purpose
To improve physical activity and outcomes related to high blood pressure, diabetes, abnormal lipid levels, and obesity for reducing the risk of breast cancer in South Asian Indian immigrant women.
Who is this for?
South Asian Indian immigrant women, age 40-65 years, who do not have breast cancer, are physically inactive, and speak Hindi.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a Fitbit</li> <li class="seamTextUnorderedListItem">Treatment plan to increase physical activity</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Body measurements, 2 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bollywood-style group dance, virtual, 1-hour sessions, twice a week for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Body measurements, 2 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a Fitbit</li> <li class="seamTextUnorderedListItem">Treatment plan to increase physical activity</li> <li class="seamTextUnorderedListItem">Bollywood-style group dance, virtual, 1-hour sessions, twice a week for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Body measurements, 2 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Body measurements, 2 times within 6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer develops an average of 5-10 years earlier in South Asian Indian immigrant women than in white women.</li> <li class="seamTextUnorderedListItem">The risk of breast cancer is more than twice as high in South Asian Indian immigrant women with high blood pressure, diabetes, abnormal lipid levels, and obesity than in white women with these conditions.</li> <li class="seamTextUnorderedListItem">This study aims to use a culturally appropriate exercise program to improve physical activity, blood pressure, diabetes, lipid levels, and obesity to reduce the risk of breast cancer in South Asian Indian immigrant women.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06827704' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
6

NEAREST SITE: 2264 miles
UPMC Magee Womens Hospital
Pittsburgh,PA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT06218303

Vaccine to Prevent Breast Cancer for Women with ER+ DCIS

A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ Scientific Title

Purpose
To study the safety and ability of an experimental MUC1 peptide vaccine to prevent breast cancer in people with DCIS.
Who is this for?
Postmenopausal women with stage 0 (DCIS) estrogen receptor positive (ER+) breast cancer who are planning to receive surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MUC1 peptide vaccine with Poly ICLC (Hiltonol®), by injection, 3-4 times within 3-9 months</li> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Not all DCIS will progress to invasive breast cancer.</li> <li class="seamTextUnorderedListItem">Vaccines for DCIS may allow for less treatment. </li> <li class="seamTextUnorderedListItem">The MUC1 peptide vaccine is an experimental immunotherapy. The vaccine targets MUC1, which is a protein expressed by DCIS.</li> <li class="seamTextUnorderedListItem">Poly ICLC (Hiltonol®) is an immunotherapy that stimulates immune cells to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06218303' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
7

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: 4 visits over 5 years

PHASE: NA

NCT ID: NCT07294703

Understanding Genetic and Lifestyle Factors That Affect Breast Cancer Risk

Genomic and Non-Genomic Factors Associated With Breast Cancer Risk Factors and Outcomes Scientific Title

Purpose
To understand how genetic and non‑genetic factors are associated with breast cancer risk and recurrence.
Who is this for?
Women with an abnormal finding on a breast exam or imaging test; or newly diagnosed with stage 0 (DCIS), stage I, stage II, stage III breast cancer who are planning to have surgery. Must be receiving care at Memorial Sloan Kettering (MSK).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and tissue samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of this study is to understand why breast cancer risk and outcomes, including recurrence, may be different for people with different backgrounds by looking at genetic information, blood and tissue samples, and survey responses.</li> <li class="seamTextUnorderedListItem">Collecting samples of blood and tissue from patients with and without breast cancer can help determine which factors may be linked to breast cancer risk and outcomes.</li> <li class="seamTextUnorderedListItem">This is a research only study and does not provide cancer treatment.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07294703' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/genetic-testing.html' target='_blank'>American Cancer Society: Genetic Counseling and Testing for Breast Cancer Risk</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing for Breast Cancer</a> </li></ul>
See more
8

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: At least 2 visits within 4 months

PHASE: NA

NCT ID: NCT06322888

Exercise to Reduce the Risk of Breast Cancer for Women With Dense Breasts

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) Scientific Title

Purpose
To study how exercise might lower the risk of developing breast cancer by studying changes that occur in breast tissue and blood.
Who is this for?
Women 18-59 years old with dense breasts on a mammogram within the past year and exercise less than 1 hour every week. You must not have a history of breast cancer, be pregnant or breastfeeding, or be receiving hormonal birth control or hormone replacement therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, in person or virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Exercise journal</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Blood test, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2 : Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Blood test, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> followed 3 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, 3 months (optional)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Greater physical activity is associated with a lower risk of breast cancer.</li> <li class="seamTextUnorderedListItem">Exercise may change markers in blood and breast tissue that play a role in breast cancer development.</li> <li class="seamTextUnorderedListItem">If you are in group 1, the exercise program includes aerobic and resistance training exercise with a certified exercise trainer.</li> <li class="seamTextUnorderedListItem">If you are in group 1, a FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to you. Hand weights will be returned at end of study.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06322888' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more